1
|
Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu YW, Shih T, Loecke D, Joshi A, Saad O, Yi JH, Girish S. Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Clin Pharmacol Drug Dev 2013; 2:11-24. [PMID: 27121556 DOI: 10.1002/cpdd.9] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2012] [Accepted: 09/24/2012] [Indexed: 02/06/2023]
Abstract
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in development for human epidermal growth factor receptor 2 (HER2)-positive cancer. Drugs in development are generally tested for their effects on QT interval, prolongation of which is associated with the potentially fatal arrhythmia torsades de pointes. In addition, an association between left ventricular dysfunction and other HER2-directed agents has been documented. This multicenter, phase 2 study, TDM4688g, assessed the safety and pharmacokinetic characteristics of T-DM1 (3.6 mg/kg every 3 weeks) in patients with previously treated HER2-positive metastatic breast cancer, and the safety of pertuzumab plus T-DM1, an anti-HER2 extracellular domain antibody, in patients with early disease progression on T-DM1 alone. The primary end point was the change in QTc interval from baseline to each postbaseline time point, adjusted for heart rate using Fridericia's correction. T-DM1 had no clinically relevant effect on QTc interval. The observed upper limit of the one-sided 95% confidence interval was below the 10-millisecond threshold of safety concern. The safety and efficacy of single-agent T-DM1 was consistent with that observed in previous studies. Pertuzumab plus T-DM1 was generally well tolerated with no new safety signals. These results support further investigation of T-DM1 as a single agent and with pertuzumab.
Collapse
Affiliation(s)
| | - Bei Wang
- Genentech, Inc., San Francisco, CA, USA
| | | | | | | | - Ted Shih
- Genentech, Inc., San Francisco, CA, USA
| | | | | | - Ola Saad
- Genentech, Inc., San Francisco, CA, USA
| | | | | |
Collapse
|
2
|
Pilkington NCV, Trotter MWB, Holden SB. Multiple Kernel Learning for Drug Discovery. Mol Inform 2012; 31:313-22. [PMID: 27477100 DOI: 10.1002/minf.201100146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Accepted: 03/12/2012] [Indexed: 01/04/2023]
Abstract
The support vector machine (SVM) methodology has become a popular and well-used component of present chemometric analysis. We assess a relatively recent development of the algorithm, multiple kernel learning (MKL), on published structure-property relationship (SPR) data. The MKL algorithm learns a weighting across multiple kernel-based representations of the data during supervised classifier creation and, thereby, may be used to describe the influence of distinct groups of structural descriptors upon a single structure-property classifier without explicitly omitting any of them. We observe a statistically significant performance improvement over a conventional, single kernel SVM on all three SPR data sets analysed. Furthermore, MKL output is observed to provide useful information regarding the relative influence of five distinct descriptor subsets present in each data set.
Collapse
Affiliation(s)
- Nicholas C V Pilkington
- University of Cambridge Computer Laboratory, 15 JJ Thomson Avenue, Cambridge, CB3 0FD, UK phone: +44 (0)1223 763725
| | - Matthew W B Trotter
- Anne McLaren Laboratory for Regenerative Medicine & Department of Surgery, University of Cambridge, UK.,Celgene Institute for Translational Research Europe (CITRE), Sevilla, Spain
| | - Sean B Holden
- University of Cambridge Computer Laboratory, 15 JJ Thomson Avenue, Cambridge, CB3 0FD, UK phone: +44 (0)1223 763725.
| |
Collapse
|
3
|
Rayan A, Marcus D, Goldblum A. Predicting Oral Druglikeness by Iterative Stochastic Elimination. J Chem Inf Model 2010; 50:437-45. [DOI: 10.1021/ci9004354] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Anwar Rayan
- Molecular Modeling and Drug Design Lab and the Alex Grass Center for Drug Design and Synthesis, Institute of Drug Research, The Hebrew University of Jerusalem 91120 Israel
| | - David Marcus
- Molecular Modeling and Drug Design Lab and the Alex Grass Center for Drug Design and Synthesis, Institute of Drug Research, The Hebrew University of Jerusalem 91120 Israel
| | - Amiram Goldblum
- Molecular Modeling and Drug Design Lab and the Alex Grass Center for Drug Design and Synthesis, Institute of Drug Research, The Hebrew University of Jerusalem 91120 Israel
| |
Collapse
|